Interstitial pneumonitis in a patient with melanoma treated with the high dose interferon alpha 2b regimen.
Siegelmann-Danieli
Nava
N
Department of Hematology and Oncology, Geisinger Medical Center, Danville, PA 17822-2001, USA. nsdanieli@geisinger.edu
Bardo
Michaelene
M
Law
Amy
A
Fisk
David
D
Bernath
Albert
A
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000628:therapy; D008545:Melanoma / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D011111:Polymyalgia Rheumatica / Q000150:complications / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011241:Prednisone